Use of GLP-1 peptides

• US 20070161568A1
• Filed: 03/05/2007
• Published: 07/12/2007
• Est. Priority Date: 11/12/1996
• Status: Abandoned Application

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: Thim, Lars, Astrup, Arne, Wulff, Birgitte, Knudsen, Liselotte, Judge, Martin, Holst, Jens
• Application Number:
  US11/714,000
• Publication Number:
  US 20070161568A1
• Time in Patent Office: Days
• US Class Current: 514/4.900
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.

Claims

1-19. -19. (canceled)

20. A pharmaceutical composition for peripheral administration comprising a compound GLP-1(1-45) or a fragment or an analogue thereof for the prophylaxis or treatment of diseases or disorders associated with impaired appetite regulation.

21. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(1-39) or an analogue thereof.

22. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(1-38) or an analogue thereof.

23. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(1-37) or an analogue thereof.

24. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(1-36) or an analogue thereof.

25. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(1-35) or an analogue thereof.

26. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(1-34) or an analogue thereof.

27. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(7-45) or an analogue thereof.

28. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(7-39) or an analogue thereof.

29. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(7-38) or an analogue thereof.

30. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(7-37) or an analogue thereof.

31. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(7-36) or an analogue thereof.

32. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(7-35) or an analogue thereof.

33. The pharmaceutical composition of claim 20, wherein the compound is GLP-1(7-34) or an analogue thereof.

34. The pharmaceutical composition of claim 20 comprising the C-terminal amide of the compound GLP-1(1-45) for use in the suppression of appetite or induction of satiety.

35. The pharmaceutical composition of claim 20 for the prophylaxis or treatment of obesity.

36. A method of treating or preventing diseases or disorders associated with impaired appetite regulation or feeling of satiety, the method comprising administering to an individual in need of such treatment a pharmaceutical composition according to claim 20.

37. A method of treating or preventing diseases or disorders associated with impaired appetite regulation or feeling of satiety, the method comprising administering to an individual in need of such treatment a pharmaceutical composition according to claim 34.

38. A method of treating or preventing obesity, the method comprising administering to an individual in need of such treatment a pharmaceutical composition according to claim 20.

39. A method of treating or preventing obesity, the method comprising administering to an individual in need of such treatment a pharmaceutical composition according to claim 34.